<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Craig Lipset on Medium]]></title>
        <description><![CDATA[Stories by Craig Lipset on Medium]]></description>
        <link>https://medium.com/@lipset?source=rss-895646279686------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*mVFZt6_rgV7TBXb5TKjHvQ.jpeg</url>
            <title>Stories by Craig Lipset on Medium</title>
            <link>https://medium.com/@lipset?source=rss-895646279686------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 05:45:20 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@lipset/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[All Research Participants Deserve the Presidential Experience]]></title>
            <link>https://lipset.medium.com/all-research-participants-deserve-the-presidential-experience-8500dbdd7e05?source=rss-895646279686------2</link>
            <guid isPermaLink="false">https://medium.com/p/8500dbdd7e05</guid>
            <category><![CDATA[clinical-trials]]></category>
            <category><![CDATA[patient-experience]]></category>
            <category><![CDATA[patient-engagement]]></category>
            <category><![CDATA[clinical-research]]></category>
            <category><![CDATA[pharmaceutical]]></category>
            <dc:creator><![CDATA[Craig Lipset]]></dc:creator>
            <pubDate>Sun, 04 Oct 2020 19:48:24 GMT</pubDate>
            <atom:updated>2020-10-05T14:20:26.324Z</atom:updated>
            <content:encoded><![CDATA[<p>This week marked a remarkable moment for us all. Regardless of political affiliations, we all paused with the news that President Trump had tested positive for SARS-CoV-2. The world watched as the sitting the President of the United States boarded Marine One on the south lawn of the White House heading to be admitted for care at Walter Reed National Military Medical Center. We read with intrigue what treatments the President may receive, with many surprised by the answer: an experimental medicine still in clinical trials.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5-wr-y6J9CulvKECsY20SA.jpeg" /><figcaption>“Marine One Lands on the South Lawn” by The White House is marked under CC PDM 1.0</figcaption></figure><p>Over the course of the pandemic, the existence of clinical trials has risen from the shadows of the medical elite to become a prominent fixture in mainstream conversation. From political briefings to news headlines to the Presidential Debate, friends and neighbors are all tracking phases of clinical trial progress for COVID-19 therapeutics and vaccines with the hope they may bring some return to normalcy.</p><p>As recently as 2019, <a href="https://www.ciscrp.org/wp-content/uploads/2019/12/General-Perceptions-and-Awareness-Report-04DEC.pdf">less than half of the population</a> indicated having heard about a trial seeking volunteers in the prior six months. Today the world sees the call for participation all around them; in the United States tens of thousands have already volunteered to participate in clinical trials for COVID-19 vaccines, and it is estimated that <a href="https://time.com/5894798/need-volunteers-covid-19-vaccine-trials/">over 1 million will have volunteered </a>around the world by the time vaccines become widespread.</p><p><a href="https://twitter.com/PressSec/status/1312122950133272576?s=20">When it was announced</a> that President Trump had received a dose of Regeneron’s REGN-COV2 investigational antibody cocktail, he likely became the first President in modern history to take a medicine <a href="https://clinicaltrials.gov/ct2/show/NCT04426695">still in clinical trials</a> and not yet approved by the FDA. While the REGN-COV2 clinical trial is listed as ongoing through late January 2021, just days prior to the President’s diagnosis <a href="https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and">the company posted very promising data</a> from the first 275 patients in the study.</p><p>The President was not enrolled as a randomized participant in the clinical trial; rather <a href="https://investor.regeneron.com/static-files/fd58ba6a-f401-47b0-9d65-cfb01c313ec6">he received access through “compassionate use”</a> (also referred to as “expanded access”). Physicians submit requests for compassionate use to the manufacturer of a medicine still in clinical trials when they have a patient meeting specific criteria: (1) a life-threatening condition, (2) no other approved treatment options, (3) not eligible to participate in the trial, (4) the potential benefits outweigh the potential risks, and (5) doing so will not adversely impact the ongoing trial.</p><blockquote><strong>While he may not be enrolled as a clinical trial participant, the President is participating in a clinical development program for a new medicine.</strong></blockquote><p><a href="https://www.fda.gov/news-events/expanded-access/expanded-access-information-patients">A compassionate use program is run with FDA permission and oversight</a>. Data from patients receiving compassionate use must still be monitored for safety, and any safety findings will still be submitted to the FDA and likely considered alongside any future regulatory submission.</p><p>Of course, clinical research participation is hardly new. It is estimated that upwards of<a href="http://info.trialscout.com/find-the-five"> 5 million people have participated in clinical trials over the last decade</a>. While we are all watching the President’s experience with an investigational medicine, what might others expect from their research participation experience?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/724/1*dhFnoXMJeoqPKIR6oH_AtQ.jpeg" /><figcaption><a href="https://www.flickr.com/photos/54591706@N02/34033294061">“Clinical Trial Participant Receives Injection”</a> by <a href="https://www.flickr.com/photos/54591706@N02">NIAID</a> is licensed under <a href="https://creativecommons.org/licenses/by/2.0/?ref=ccsearch&amp;atype=rich">CC BY 2.0</a></figcaption></figure><p>Research participants can expect to have greater say in the design of studies — as biotechnology and pharmaceutical research sponsors increasingly <a href="https://www.ncbi.nlm.nih.gov/books/NBK535689/">commit to including the voice of the patient</a> in how they design their studies.</p><p>Research participants today can expect to see improved access to information — whether information to help learn about and find trials, resources to ease participation during the trial, and even information after their study such as study results and even personal health data.</p><p>Research participants can expect improved access to trials — from ride-sharing and travel support to tools that “<a href="https://www.ctti-clinicaltrials.org/projects/decentralized-clinical-trials">decentralize trials</a>” and enable remote, at-home participation.</p><p>Research participants can also expect tools to capture data and outcomes that matters to them — as studies employ <a href="https://www.fda.gov/industry/prescription-drug-user-fee-amendments/fda-led-patient-focused-drug-development-pfdd-public-meetings">patient-focused drug development</a> to ensure that endpoints are meaningful and leveraging new digital solutions (such as sensors, wearables, and artificial intelligence) to make it easier to collect that data.</p><blockquote><strong>But while the research community has been making significant investments in the experience of participants in clinical trials, it is hardly up to a “Presidential experience”.</strong></blockquote><p>Despite good intentions the experience of participants today can still be highly inconsistent, involving a range of disconnected tools and resources. Many participants still face too many out-of-pocket expenses without consistent reimbursement(whether for travel or time off from work) as well as significant travel burden. Many participants still lack consistent and available information resources — from finding a study through consent, participation, and results.</p><p>The quoteworthy business consultant Peter Drucker is attributed with saying “you can’t manage what you can’t measure”. It is only in recent years that the research community has began to appreciate the potential and impact of measuring the experience of research participants.</p><p>Last year TransCelerate Biopharma — a non-profit collaboration of 20 of the world’s large pharmaceutical R&amp;D organizations — published their <a href="https://www.transceleratebiopharmainc.com/initiatives/patient-experience/">patient experience toolkit</a> to encourage research sponsors to measure and learn from the experience of participants in research studies.</p><p>Likewise, <a href="https://www.trialscout.com/">innovative companies have risen to the opportunity</a>, inviting research participants to capture and share their experience in clinical trials. These new approaches bring fresh transparency to benefit research sites and sponsors (to improve their patient experience measures) as well as support patients and caregivers while deciding if participation is right for them.</p><p>The COVID-19 pandemic has brought significant health and economic suffering to the planet, but has also raised the visibility of clinical trials and research participant as vital to our future. While the President may have received an investigational medicine still in clinical trials, the research community still has work to do to deliver a “Presidential experience” for all research participants.</p><p>Those who decide to participants are often referred to as “<a href="https://www.ciscrp.org/events/medical-heroes-appreciation/#:~:text=What%20is%20a%20Medical%20Hero,of%20participation%20in%20clinical%20research.">Medical Heroes</a>”. The work of the research community is not done until participants receive an experience that lives up to that honor.</p><p><em>Disclosure: Craig Lipset is the founder of advisory firm Clinical Innovation Partners, and serves on the faculty at Rutgers University (Health Informatics) and the University of Rochester (Center for Health + Technology). He is a member of the Board of Directors for Circuit Clinical (creator of TrialScout), as well as for the non-profit Foundation for Sarcoidosis Research and MedStar Health Research Institute. Lipset was previously Head of Clinical Innovation at Pfizer during which time he served on the founding Oversight Committee for TransCelerate Biopharma as well as the Program Committee for the Clinical Trials Transformation Initiative’s Mobile Trials project.</em></p><p>LinkedIn: linkedin.com/in/lipset/<br>Twitter: twitter.com/craiglipset<br>YouTube: <a href="http://bit.ly/CraigTalksClinical">http://bit.ly/CraigTalksClinical</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8500dbdd7e05" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>